OECI General Assembly – Poznań - June 22, 2018



OUTCOMES RESEARCH WORKING GROUP

OECI40

20th June 2018 15.00 – 18.00

SUMMARY OF DISCUSSION



SESSION AIMS

- **1. Agree on WG objectives**
- 2. Define a list of outcomes indicators available among OECI centres
- **3. Cancers more suitable for outcomes studies**
- **4. OECI centres willing to adhere**
- 5. Preferred way forward which funding modality
- 6. OUTCOMES WG NEXT STEPS



WHY A WG ON CANCER OUTCOMES RESEARCH IN OECI?

to create a system of integrated clinical data

FINAL AIM

the construction of well profiled patient cohorts using data available among our centres, possibly integrated with population registry data

Including all patients (real world)



DECISIONS ON OUTCOMES MEASUREMENT

- indicators should be already available among OECI centres
- simple and standardised
- enabling us to produce results in a short term
- in conformity with OECI accreditation system
- potentially useful for more than one site



EXAMPLES from OECI accreditation system items

- Adhesion to standard care (e.g. Radiotherapy in BCS)
- 30-day postoperative mortality, 90-day reintervention
- Relapse, Disease-free survival



CONS

accreditation items are finalised to describe processes and quality in the centres

they may be used for studying outcomes, however this is not their principal aim

PROS

the added value of using A&D criteria is their validation

OECI General Assembly – Poznań - June 22, 2018



OTHER ISSUES DISCUSSED...

- Comorbidity and anticancer treatment
- % Multiple Myeloma patients undergoing bone marrow transplantation
- Quality of life
 standard indicators, proms
- Overtreatment



SUITABLE CANCER SITES

Colorectal Breast One rare: multiple myeloma, sarcoma?



PREFERRED WAY FORWARD- FUNDING MODALITY

one large project organised in WPs of which one will be on cancer outcomes

OPTIONS

•SC1-DTH-01-2019: Big data andd Artificial Intelligence for monitoring health status and quality of life after the cancer treatment

•Innovative Medicine Initiative (IMI) out in 2019

•Other?



WHO IS ON BOARD?

Belgium Institut Jules Bordet Czech Republic Masaryk Memorial Centre Estonia Tartu University Hospital Finland Turku University Cancer Centre France Institute Curie Italy over 10 centres under the coordination of INT - ACC The Netherlands IKNL, Rijnstaad **Poland Greater Poland Cancer Centre** Portugal Instituto Portugues de Oncologia, IPO- PORTO **Slovenia Oncology Institute Lubljiana Spain Institut Catala Oncologia**



WHO ARE WE?

- 22 centres from 11 EU countries
- **All accredited OECI centres**
- All have clinical registries
- All have a connection with population data

READY TO START!



NEXT STEPS

Autumn 2018: WG meeting to prepare protocol for a call application

See you in Brussels or Milan!